ArticleSocial psychiatry and psychiatric epidemiology2026
Suicidal ideation associated with daridorexant treatment in insomnia patients: Comparator-restricted disproportionality analysis and assessment of potential heterogeneity in reporting patterns.
Article in Social psychiatry and psychiatric epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeDaridorexant, a novel dual orexin receptor antagonist, holds promise for managing insomnia. Although previous studies have identified a significant signal for suicidal ideation associated with daridorexant when compared with all other drugs, the significance when compared specifically with insomnia medications and the potential differences in reporting patterns of suicidal ideation across subgroups remain unclear.
methodsThis study utilized the data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Comparator-restricted disproportionality analyses were conducted using the reports with insomnia indication and commonly prescribed insomnia medications as comparators. Sensitivity analyses, stratified analyses, and subgroup comparative analyses were then performed to explore the potential differences in reporting patterns of suicidal ideation across subgroups.
resultsThe signal for suicidal ideation was no longer significant based on comparator-restricted disproportionality analyses. Sensitivity analyses revealed a reduction in the signal strength for suicidal ideation after excluding reports with depression-related co-reported adverse events, and depression was the only significant concurrent event that occurred simultaneously with suicidal ideation, suggesting that the co-reported depression may partly contribute to the reporting of suicidal ideation. Additionally, there may be potential differences in reporting patterns of daridorexant-associated suicidal ideation across subgroups.
conclusionsAlthough prior studies have identified a significant signal for suicidal ideation associated with daridorexant, the underlying relationship is likely multifactorial, with potential confounders such as underlying insomnia and co-reported depression. In addition, this study underscores the potential need for further verification of the differences in reporting daridorexant-associated suicidal ideation. The establishment of a definitive pharmacoepidemiological relationship between daridorexant and suicidal ideation warrants further research.
Indexed as
Identifiers
42888253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.